Real-world evidence is increasingly demonstrating tobacco harm reduction (THR) in action, so why do many public health bodies and regulators remain sceptical? Joe Thompson, Group Science & Regulatory ...
A study led by Karl Landsteiner University shows that the disease affects whole-brain communication networks, and that this may help predict survival.Krems, Austria, 21 April 2026 – Glioblastoma, the ...
LONDON, UK and COPENHAGEN, Denmark – April 22, 2026 – Coulter Partners, the global expert building leadership teams for ...
Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the ...
Saint Charles, Mo., April 16, 2026 – D2 Solutions, a healthcare consulting and technology company focused on market access, reimbursement and patient support, has acquired ProModRx, a cloud-based ...
KAISERSLAUTERN, Germany, April 20, 2026 / Biotech Newswire / -- Freudenberg Medical, a global contract design and manufacturing partner to the medical device and biopharma industry, announced the ...
TauRx today announced results from a confirmatory study evaluating hydromethylthionine mesylate in participants with mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease ...
Panthera Biopartners (Panthera), the leading UK based clinical trial Site Management Organisation (SMO), has announced the acquisition of Óbudai Egészségügyi Centrum Kft (OEC), Hungary’s leading ...
SAN DIEGO, USA, April 21, 2026 / Biotech Newswire / -- Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced a strategic partnership with ...
Speech could be a key clinical marker in neurodegenerative disease drug trials, says leading biotech
SynaptixBio, the only company licensed to commercialise a treatment for the rare, deadly disease H-ABC, says families value the ability to communicate more than other disease impacts Speech is rapidly ...
Panthera Biopartners (Panthera), the leading UK based clinical trial Site Management Organisation (SMO), has announced the acquisition of Óbudai Egészségügyi Centrum Kft (OEC), Hungary’s leading ...
Study of CAL101, which targets a novel upstream pathway implicated in fibrotic disease, enrolls 161 patients more than six months ahead of plan; topline data expected Q1 2027Drug candidate, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results